Browse News

Found 80 articles

• ORYZON to Present a Corporate Update and to Hold Multiple Virtual Corporate Activities in January 2021

  1/4/2021

  To present recent progress of clinical pipeline at the H.C. Wainwright Bioconnect Conference Will participate in LifeSci Advisors’ 10 th Annual LifeSci Advisors Corporate Access Event 2021 Will participate in Edison’s Open House – Global Healthcare 2021 Will present and participate at ACCESS CHINA Forum @JPM Week 2021 All virtual events during three consecutive weeks in January

• ORYZON Launches Pioneering Schizophrenia Precision Medicine Study In Collaboration With Columbia Psychiatry

  12/17/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, announced today the start of a precision medicine collaboration in schizophrenia (SCZ) with researchers from Columbia University in New York, Dr. Joseph Gogos, Dr. Sander Markx and Dr. Jeffrey Lieberman.

• atai Life Sciences Appoints New Chief Financial Officer and Chief Medical Officer

  12/16/2020

  atai Life Sciences ("atai" or the "Company"),  a global biotech company developing psychedelic and non-psychedelic compounds for various mental health indications, has announced the appointment of Greg Weaver as Chief Financ

• 

  Clinical Catch-Up: December 7-11

  12/14/2020

  It was an unusually busy week for clinical trial updates, largely because of the annual ASH meeting from Sunday December 5 through Wednesday December 9. There were also other meetings and the usual corporate updates.

• ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020

  12/7/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presents new positive efficacy data from its ongoing Phase II ALICE trial, which is investigating iadademstat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML)

• 

  Clinical Catch-Up: November 9-13

  11/16/2020

  It was a particularly busy week for clinical trial updates, mostly because of several virtual conferences, including the virtual American Heart Association Scientific Sessions 2020 and The Society for Immunotherapy of Cancer’s Annual Meetings. Here's a look.

• ORYZON to Present Further Positive Efficacy Data From Iadademstat ALICE Phase IIa Trial at the 62nd Congress of the American Society of Hematology

  11/11/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the company will present additional preliminary safety and efficacy data from one of its ongoing Phase IIa clinical trials with iadademstat

• ORYZON Receives Approval to Start PORTICO Phase IIb Trial with Vafidemstat in Borderline Personality Disorder

  11/10/2020

  Oryzon announced today that it has received approval from the Spanish Drug Agency (AEMPS) for its Clinical Trial Application (CTA) to conduct a Phase IIb clinical trial with vafidemstat in patients with Borderline Personality Disorder (BPD).

• Oryzon Announces Appointment of Dr. Torsten Hoffmann as Global R&D Director and Retirement of Dr. Tamara Maes

  11/2/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Tamara Maes will be retiring as a Chief Scientific Officer at Oryzon in 2020.

• ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

  10/26/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2020 and provided an update on recent developments. Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon has successfully focused on the execution of its ongoing clinical

• ORYZON Publishes Paper in Journal of Clinical Oncology Demonstrating Relevance of Iadademstat in Leukemia

  10/15/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces the publication of a scientific paper in the peer-reviewed international medical journal, Journal of Clinical Oncology.

• ORYZON Presents Efficacy and Safety Results of its CLEPSIDRA Trial with Iadademstat in ED-SCLC Patients at ESMO-2020

  9/17/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announces today pre-final data from CLEPSIDRA, a Phase II trial investigating iadademstat in combination with standard of-care in relapsed extensive disease (ED) small cell lung cancer (SCLC) patients.

• ORYZON to present at upcoming international conferences - Sep 08, 2020

  9/8/2020

  Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that Executive Directors of the company will present at several reputed international conferences in September, all of them to be held virtually.

• ORYZON First Half Ended June 30, 2020 Results and Corporate Update

  7/22/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2020 and provided an update on recent developments.

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

• ORYZON Raises its Share Capital by EUR 20 Million

  7/7/2020

  Oryzon Genomics, S.A. (MAD: ORY) (" Oryzon " or the " Company "), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical needs, today announced that on June 25 th it agreed to sell 7,273,000 new common shares (the “ New Shares ”) at a price of 2.75 euros per share, representing a 10.7% discount from the closing price of June 24, for an aggregate amount of EUR 20 Million (the

• ORYZON Presents Final Data From its Phase IIa Clinical Trial REIMAGINE at the 28th European Congress of Psychiatry, EPA 2020

  7/6/2020

  Vafidemstat reduces aggression in the three psychiatric disorders studied Patients with Borderline Personality Disorder show a more relevant improvement The company will shortly start a Phase IIb trial in this indication

• ORYZON to Present at Upcoming Virtual International Conferences

  7/2/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Executive Directors of the company will present at several r

• ORYZON Enters Into Pioneering Precision Medicine Collaboration with La Paz Hospital in Madrid for Phelan-McDermid Syndrome

  6/19/2020

  Phelan-McDermid Syndrome is thought to be one of the causes of Autism Spectrum Disorder Patient stratification to be carried out prior to clinical study with Oryzon’s vafidemstat LSD1 inhibition may open the way to precision medicine in certain subtypes of CNS disorders MADRID, Spain and CAMBRIDGE, Mass., June 19, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in dis

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.